Inhaled nitric oxide treatment of children with pulmonary hypertension after cardiac surgery

Citation
J. Breuer et al., Inhaled nitric oxide treatment of children with pulmonary hypertension after cardiac surgery, PROG PEDI C, 9(2), 1998, pp. 73-83
Citations number
58
Categorie Soggetti
Pediatrics
Journal title
PROGRESS IN PEDIATRIC CARDIOLOGY
ISSN journal
10589813 → ACNP
Volume
9
Issue
2
Year of publication
1998
Pages
73 - 83
Database
ISI
SICI code
1058-9813(199811)9:2<73:INOTOC>2.0.ZU;2-H
Abstract
The presence of pulmonary hypertension in children with a congenital heart defect carries the risk of considerable problems of management immediately after corrective surgery. To evaluate whether inhaled nitric oxide (NO) com plements other routine therapeutic measures to lower pulmonary artery press ure, 28 infants and children (ages, 0.85 +/- 0.19 years) with this conditio n were studied within the first few days after surgery. Hemodynamics and/or oxygen saturations were significantly improved by NO inhalation (initial c oncentration, 15 +/- 1.8 ppm) in 27 patients (96%). Mean pulmonary arterial pressure (PAP) declined significantly from 45 +/- 5.8 to 27 +/- 3.1 mmHg, whereas there were significant increases in mean systemic arterial pressure (55 +/- 1.9 to 59 +/- 1.8 mmHg) and arterial oxygen saturation (SaO(2), 90 +/- 1.9 to 97 +/- 1.1%). The changes in PAP (ED50: 0.29 +/- 0.07 ppm NO) a nd SaO(2) (ED50: 0.21 +/- 0.04 ppm NO) were dose-dependent with no signific ant difference in ED,, values. The NO-induced pulmonary vasodilation was in dependent of the concomitant reduction in arterial carbon dioxide tension. In a case-control study of a subgroup of 18 patients and 35 matched control s, inhaled NO significantly reduced the frequency of pulmonary hypertensive crises by 83% and lowered the mortality rate from 14.2% to zero. During lo w-dose NO inhalation there was no detectable formation of methemoglobin or significant production of nitric dioxide (NO,), and no disturbance of plate let aggregation or leukocyte adhesion. It is concluded that in children und ergoing cardiac bypass surgery, low-dose inhaled NO improves hemodynamics a nd oxygenation, and reduces the frequency, severity, and mortality of pulmo nary hypertensive crises during perioperative intensive care. We recommend a dose range of 1-10 ppm NO for routine use, and an absolute upper dose lim it of 40 ppm NO to avoid potential adverse side effects. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.